Alkol Biotech

alkolbiotech.co.uk

Alkol Biotech is a research company focused on the development of new plant varieties adapted to the needs of specific biofuel markets. The company adapts plant varities to grow in colder and dryer climates, offering better resistance to pests and diseases, and higher productivities. This allows the development of healthy biofuel markets in countries which otherwise have to import biomass in order to produce biofuels sustainably. Our first crop is a sugarcane hybrid focused on the european market for cellulosic ethanol production. It will offer up to 200 tons of biomass per hectare, 31% fiber, and will be the main source of biomass for Europe's 5% 2nd generation limit in the year 2020.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

news image

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

news image

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

news image

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More
news image

MEDICAL

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More
news image

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More
news image

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us